NGNE CIK: 1404644

Neurogene Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−47.6
FY22:
−52.8
FY23:
−51.4
FY24:
−70.6
FY25:
−77.2
Change from FY21 to FY25
millions USD
FY21:
−3.26
FY22:
−2.23
FY23:
25.6
FY24:
−125
FY25:
14.0
Change from FY21 to FY25
millions USD
FY21:
0.73
FY22:
66.5
FY23:
92.5
FY24:
184
FY25:
30.4
millions USD
FY21:
−50.1
FY22:
11.5
FY23:
66.7
FY24:
−11.8
FY25:
−32.7
(positive)
Change from FY21 to FY25
millions USD
FY21:
−50.8
FY22:
−55.1
FY23:
−51.7
FY24:
−71.4
FY25:
−78.4

All amounts in millions USD Data source:SEC EDGAR